SVRA Savara

Savara Announces Participation in Upcoming Healthcare Conferences

LANGHORNE, Pa.--(BUSINESS WIRE)--

(Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats.

Jefferies London Healthcare Conference, November 19-21, 2024

Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT

Piper Sandler 36th Annual Healthcare Conference, December 3-5, 2024

Fireside Chat: December 3rd, 8:30am ET/5:30am PT

The live webcasts and subsequent replays will be available on the “Events & Presentations” section of the Company’s corporate website at and will be archived for 90 days.

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at , X: , LinkedIn:

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.

EN
13/11/2024

Underlying

SVRASavara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Savara

 PRESS RELEASE
Free
SVRA SAVARA

Savara Announces Participation in Upcoming Healthcare Conferences

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats. Jefferies London Healthcare Conference, November 19-21, 2024 Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT Piper Sandler 36th Annual Healthcare Conference, December 3-5, 2024 Fireside Chat: December 3rd, 8:30am ET/5:30am PT The live webcasts and subsequent replays will be available...

November 13, 2024 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara Reports Third Quarter 2024 Financial Results and Provides Busin...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update. “After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Sa...

November 12, 2024 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Co...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be available on Savara's website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation sol...

November 4, 2024 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar ...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of The Balancing Act®, sponsored by Savara and featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP), is airing on Lifetime TV’s Behind the Mystery™ a recurring series on The Balancing Act® television show devoted to advocating for people with rare and genetic diseases. The episode centers on the diagnostic journey of an aPAP patient and includes insights from Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, U...

October 22, 2024 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara Announces New Employment Inducement Grant

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On October 17, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 95,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 95,000 shares of the Company’s common stock. These equity awa...

October 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch